# Intestinal Microbiome Post-Azythromycin/Albendazole Treatment

> **NCT03032042** · PHASE4 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Helminth Infection

## Interventions

- **DRUG:** Azithromycin
- **DRUG:** Albendazole
- **DRUG:** Delayed treatment

## Key facts

- **NCT ID:** NCT03032042
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2017-02
- **Final completion:** 2018-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We were not able to secure IRB approval in the timeline necessary to do this study.
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032042, "Intestinal Microbiome Post-Azythromycin/Albendazole Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03032042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*